Press releases
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
- Aldeyra Therapeutics to Host Investor Roundtable Q&A
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
More ▼
Key statistics
On Friday, Aldeyra Therapeutics Inc (137:FRA) closed at 3.56, 159.88% above the 52 week low of 1.37 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.56 |
---|---|
High | 3.56 |
Low | 3.56 |
Bid | 3.45 |
Offer | 3.52 |
Previous close | 3.56 |
Average volume | 148.40 |
---|---|
Shares outstanding | 59.41m |
Free float | 48.66m |
P/E (TTM) | -- |
Market cap | 221.62m USD |
EPS (TTM) | -0.5080 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 07:20 BST.
More ▼